MA53913A - Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament - Google Patents

Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament

Info

Publication number
MA53913A
MA53913A MA053913A MA53913A MA53913A MA 53913 A MA53913 A MA 53913A MA 053913 A MA053913 A MA 053913A MA 53913 A MA53913 A MA 53913A MA 53913 A MA53913 A MA 53913A
Authority
MA
Morocco
Prior art keywords
delivery device
drug delivery
device platform
assembling drug
assembling
Prior art date
Application number
MA053913A
Other languages
English (en)
Inventor
Adam B Mccullough
Matias Melander
Rasmus Ohlenschlager
Jakob Halkjaer Pedersen
Christian Plambech
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA53913A publication Critical patent/MA53913A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/1413—Modular systems comprising interconnecting elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2207/00—Methods of manufacture, assembly or production
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00—Metal working
    • Y10T29/49—Method of mechanical manufacture
    • Y10T29/49826—Assembling or joining
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00—Metal working
    • Y10T29/53—Means to assemble or disassemble

Landscapes

  • Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Automatic Assembly (AREA)
MA053913A 2018-10-15 2019-10-15 Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament MA53913A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862745739P 2018-10-15 2018-10-15

Publications (1)

Publication Number Publication Date
MA53913A true MA53913A (fr) 2022-01-19

Family

ID=68425346

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053913A MA53913A (fr) 2018-10-15 2019-10-15 Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament

Country Status (14)

Country Link
US (1) US20210346596A1 (fr)
EP (1) EP3866889A1 (fr)
JP (2) JP2022504805A (fr)
CN (1) CN112689523A (fr)
AR (2) AR116703A1 (fr)
AU (2) AU2019359801B2 (fr)
CA (1) CA3109988A1 (fr)
EA (1) EA202191038A1 (fr)
IL (1) IL281895A (fr)
MA (1) MA53913A (fr)
MX (1) MX2021002791A (fr)
SG (1) SG11202101824VA (fr)
TW (1) TWI846741B (fr)
WO (1) WO2020081480A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220457A (es) 2020-02-13 2023-01-09 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria
MX2022010120A (es) 2020-02-18 2022-09-05 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
KR20230175245A (ko) 2021-04-23 2023-12-29 암젠 인크 변형된 항-tslp 항체
US20240190951A1 (en) 2021-04-23 2024-06-13 Amgen Inc. Anti-tslp antibody compositions and uses thereof
EP4384240A1 (fr) * 2021-08-09 2024-06-19 SHL Medical AG Procédé de fabrication d'un sous-ensemble d'un dispositif d'administration de médicament
GB2618850A (en) * 2022-05-20 2023-11-22 Tip Top Com Ltd A method of assembling a needle safety apparatus
TW202426485A (zh) 2022-10-26 2024-07-01 美商安進公司 抗ｔｓｌｐ抗體組成物及其用途
WO2024238877A1 (fr) 2023-05-18 2024-11-21 Medimmune, Llc Traitement de l'asthme dépendant des corticostéroïdes avec un anticorps anti-tslp
IL330343A (en) 2024-01-05 2026-08-01 Medimmune Llc Treatment of chronic obstructive pulmonary disease using an anti-TSLP antibody
WO2025221247A1 (fr) 2024-04-17 2025-10-23 Amgen Inc. Traitement de l'œsophagite à éosinophiles avec un anticorps anti-tslp

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
AU646822B2 (en) 1989-10-13 1994-03-10 Kirin-Amgen Inc. Erythropoietin isoforms
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US6562596B1 (en) 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US6391633B1 (en) 1997-07-23 2002-05-21 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
US6030086A (en) 1998-03-02 2000-02-29 Becton, Dickinson And Company Flash tube reflector with arc guide
US6310078B1 (en) 1998-04-20 2001-10-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as erythropoietin mimetics
US20050181482A1 (en) 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
DK1088084T3 (da) 1998-06-15 2007-01-29 Gtc Biotherapeutics Inc Erythropoietin analog-humant serumalbumin fusionsprotein
DE69935345T3 (de) 1998-10-23 2018-03-01 Amgen Inc. Methoden und zusammensetzungen zur prävention und behandlung der anämie
ATE348163T1 (de) 1998-10-23 2007-01-15 Amgen Inc Thrombopoietin substitute
ES2639020T3 (es) 1998-11-27 2017-10-25 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la substancia ósea
EP1006184A1 (fr) 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag Protéines interagissant avec le récepteur de IGF-1, gènes codant pour ces protéines et leurs utilisations
EP1169352A4 (fr) 1999-04-14 2005-05-04 Smithkline Beecham Corp Anticorps du recepteur d'erythropoietine
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
AU1099601A (en) 1999-10-22 2001-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules derived from rat brain and programmed cell death models
US20050202538A1 (en) 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2391080A1 (fr) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Formes d'erythropoietine dotees de proprietes ameliorees
JP4810042B2 (ja) 2000-01-21 2011-11-09 バイオヴェックス リミテッド ヘルペスウイルス株
AUPQ599700A0 (en) 2000-03-03 2000-03-23 Super Internet Site System Pty Ltd On-line geographical directory
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU5551601A (en) 2000-04-21 2001-11-07 Amgen Inc Methods and compositions for the prevention and treatment of anemia
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US20030191291A1 (en) 2000-09-08 2003-10-09 Kochendoerfer Gerd G. Synthetic erythropoiesis stimulating proteins
US7271689B1 (en) 2000-11-22 2007-09-18 Fonar Corporation Magnet structure
EP1345628B1 (fr) 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Conjugues d'erythropoietine (epo) avec polyethylene glycol (peg)
NZ527302A (en) 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
JP2005503127A (ja) 2001-04-04 2005-02-03 ジェンオディセ エリスロポエチン遺伝子の新規ポリヌクレオチド及びポリペプチド
HU229910B1 (hu) 2001-05-11 2014-12-29 Amgen Inc Thousand Oaks A TALL-1-hez kötõdõ peptidek és rokon molekulák
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
KR100911951B1 (ko) 2001-08-23 2009-08-13 젠맵 에이/에스 인터루킨 15 (ｉｌ-15)에 대하여 특이적인 인간 항체
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
WO2003055526A2 (fr) 2001-12-21 2003-07-10 Maxygen Aps Conjugues d'erythropoietine
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
ES2283759T3 (es) 2002-01-18 2007-11-01 Pierre Fabre Medicament Anticuerpos anti-igf-ir y sus aplicaciones.
EP1470232A1 (fr) 2002-01-31 2004-10-27 Oxford Biomedica (UK) Limited Vecteur d'expression de l'erythropoietine physiologiquement regule, destine au traitement de l'anemie
GB0202252D0 (en) 2002-01-31 2002-03-20 Oxford Biomedica Ltd Anemia
ATE363541T1 (de) 2002-03-26 2007-06-15 Lek Tovarna Farmacevtskih Verfahren für die herstellung eines gewünschten profils von erythropoietin glyko-isoformen
KR100954975B1 (ko) 2002-03-29 2010-04-30 구미아이 가가쿠 고교 가부시키가이샤 아세토락테이트 합성효소를 암호화하는 유전자
WO2003084477A2 (fr) 2002-03-29 2003-10-16 Centocor, Inc. Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations
SE0201142D0 (sv) 2002-04-16 2002-04-16 Pharmacia Ab A system and method for modification of a device and a device suitable for modification
WO2003094858A2 (fr) 2002-05-13 2003-11-20 Modigenetech Ltd. Érythropoïétine comportant une extension ctp
MXPA04011624A (es) 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7241733B2 (en) 2002-06-28 2007-07-10 Centocor, Inc. Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
WO2004002417A2 (fr) 2002-06-28 2004-01-08 Centocor, Inc. Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
WO2004009627A1 (fr) 2002-07-19 2004-01-29 Cangene Corporation Composes erythropoietiques pegyles
TW200413406A (en) 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
WO2005025606A1 (fr) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Erythropoietines a action prolongee pouvant maintenir une activite de protection tissulaire d'une erythropoietine endogene
MXPA05002594A (es) 2002-09-11 2005-05-27 Fresenius Kabi Gmbh Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon.
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US20040071694A1 (en) 2002-10-14 2004-04-15 Devries Peter J. Erythropoietin receptor binding antibodies
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
TWI320716B (en) 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
WO2004034988A2 (fr) 2002-10-16 2004-04-29 Amgen Inc. Anticorps humains neutralisants anti-ifn-$g(g) utilises comme inhibiteurs selectifs des voies de ifn-$g(g)
US20040091961A1 (en) 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
AU2003301195B2 (en) 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
US9205197B2 (en) * 2003-03-03 2015-12-08 Sanofi-Aventis Deutschland Gmbh Drug delivery device dose setting mechanism
BRPI0408317A (pt) 2003-03-14 2006-03-07 Pharmacia Corp anticorpos do receptor de igf-i para o tratamento de cáncer
CA2519113C (fr) 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Anticorps contre le recepteur du facteur de croissance 1 analogue a l'insuline et utilisations de ceux-ci
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
EP2365001A3 (fr) 2003-05-01 2012-03-28 Imclone LLC Anticorps humains dirigés contre le récepteur de facteur 1 de croissance de type insuline humaine
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
KR101163683B1 (ko) 2003-05-12 2012-07-10 아피맥스, 인크. 에리스로포이에틴 수용체에 결합하는 신규의 펩티드
PL1625156T3 (pl) 2003-05-12 2013-03-29 Affymax Inc Peptydy wiążące się do receptora erytropoetyny
JP2007530440A (ja) 2003-05-12 2007-11-01 アフィーマックス・インコーポレイテッド 新規ポリ（エチレングリコール）修飾化合物およびその用途
US7074755B2 (en) 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
WO2004108667A2 (fr) 2003-05-30 2004-12-16 Centocor, Inc. Formation de nouveaux conjugues d'erythropoietine au moyen d'une transglutaminase
WO2005001136A1 (fr) 2003-06-04 2005-01-06 Irm Llc Methodes et compositions pour la modulation de l'expression de l'erythropoietine
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
UA97086C2 (uk) 2003-07-15 2012-01-10 Емджен, Інк. Виділене людське антитіло, яке специфічно зв'язується з фактором росту нервової тканини (ngf)
EA015363B1 (ru) 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
JP2007512001A (ja) 2003-08-28 2007-05-17 バイオレクシス ファーマシューティカル コーポレイション Ｅｐｏミメティックペプチドおよび融合タンパク質
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
US20060127404A1 (en) 2003-09-30 2006-06-15 Chichi Huang Hinge core mimetibodies, compositions, methods and uses
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
NZ547168A (en) 2003-11-24 2010-05-28 Biogenerix Ag Glycopegylated erythropoietin
WO2005058967A2 (fr) 2003-12-16 2005-06-30 Pierre Fabre Medicament Nouveau recepteur hybride anti-insuline/igf-i ou recepteur hybride anti-insuline/igf-i et anticorps igf-ir et applications
EP1548031A1 (fr) 2003-12-22 2005-06-29 Dubai Genetics FZ-LLC Erythropoietin identique à la nature
EP1699821B1 (fr) 2003-12-31 2012-06-20 Merck Patent GmbH PROTEINE HYBRIDE Fc-ERYTHROPOIETINE A PHARMACOCINETIQUE AMELIOREE
EP1699920A4 (fr) 2003-12-31 2008-05-28 Centocor Inc Nouvelles proteines recombinees avec thiol libre n-terminal
US7423139B2 (en) 2004-01-20 2008-09-09 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5′-UTR
WO2005070451A1 (fr) 2004-01-22 2005-08-04 Zafena Aktiebolag Composition pharmaceutique comprenant une erythropoietine non glycosylee
WO2005084711A1 (fr) 2004-03-02 2005-09-15 Chengdu Institute Of Biological Products Erythropoietine recombinante pegylee a activite in vivo
TW200603818A (en) 2004-03-11 2006-02-01 Fresenius Kabi De Gmbh Conjugates of hydroxyethyl starch and erythropoietin
CA2560889A1 (fr) 2004-03-23 2005-10-13 Sanjay D. Khare Anticorps monoclonaux
US20050227289A1 (en) 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
CA2563874A1 (fr) 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Variants d'erythropoietine
EP1781697B1 (fr) 2004-07-07 2009-04-22 H.Lundbeck A/S Nouvelle erythropoietine carbamylee et son procede de production
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
US20060073563A1 (en) 2004-09-02 2006-04-06 Xencor, Inc. Erythropoietin derivatives with altered immunogenicity
AU2005303887A1 (en) 2004-11-10 2006-05-18 Aplagen Gmbh Molecules which promote hematopoiesis
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2006081171A1 (fr) 2005-01-24 2006-08-03 Amgen Inc. Anticorps anti-amyloide humanise
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CA2678008C (fr) 2005-06-17 2013-07-30 Imclone Systems Incorporated Antagonistes de recepteur pour le traitement de cancer osseux metastatique
WO2007000328A1 (fr) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Anticorps se fixant à un épitope sur un récepteur de facteur de croissance insulinomimétique de type 1 et leurs utilisations
DK1915398T3 (en) 2005-07-18 2016-07-04 Amgen Inc Humane anti-B7RP1 neutraliserende antistoffer
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
CN103255162A (zh) 2006-05-19 2013-08-21 格利科菲公司 促红细胞生成素组合物
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
WO2008057457A2 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
CA2667869A1 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
CA2667894A1 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
WO2008133647A2 (fr) 2006-11-07 2008-11-06 Merck & Co., Inc. Antagonistes de pcsk9
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
AR066042A1 (es) 2007-04-13 2009-07-22 Novartis Ag Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
KR20100034015A (ko) 2007-06-20 2010-03-31 아이알엠 엘엘씨 알레르기 질환 치료를 위한 방법 및 조성물
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
CN102232088A (zh) 2007-10-26 2011-11-02 先灵公司 用于治疗脂类和胆固醇疾病的抗pcsk9及方法
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US20120219558A1 (en) 2009-09-25 2012-08-30 Yan Ni Antagonists of pcsk9
CA2777698A1 (fr) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Antagonistes de la pcsk9 avec anticorps fab ax189 et ax1, et variantes afferentes
AU2010313324A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX213 and AX132 PCSK9 antagonists and variants
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
WO2012054438A1 (fr) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
CN103261230A (zh) 2010-12-22 2013-08-21 霍夫曼-拉罗奇有限公司 抗pcsk9抗体及使用方法
GB2486693B (en) * 2010-12-22 2016-05-18 Owen Mumford Ltd Autoinjectors and manufacturing systems thereof
CA2825778A1 (fr) 2011-01-28 2012-08-02 Sanofi Compositions pharmaceutiques comprenant des anticorps humains contre pcsk9
MX2013009258A (es) 2011-02-11 2013-10-17 Novartis Ag Antagonistas de pcsk9.
EP2489383A1 (fr) * 2011-02-18 2012-08-22 Sanofi-Aventis Deutschland GmbH Auto-injecteur
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EP2771050B1 (fr) * 2011-10-27 2020-06-24 Sanofi-Aventis Deutschland GmbH Composant de dispositif d'administration de médicament et procédé d'assemblage
JP5973228B2 (ja) * 2012-05-11 2016-08-23 株式会社ダイセル 注射器
EP3907237A1 (fr) 2012-12-20 2021-11-10 Amgen Inc. Agonistes du récepteur apj et leurs utilisations
US20140274874A1 (en) 2013-03-14 2014-09-18 Amgen Inc. Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
SG11201507524TA (en) 2013-03-14 2015-10-29 Amgen Inc Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
JP6663855B2 (ja) * 2014-03-28 2020-03-13 レプロ−メッド システムズ、インコーポレーテッド コンパクトな医療用ポンプ
CN107206166B (zh) * 2014-11-12 2020-12-04 诺和诺德股份有限公司 制造一系列自动注射器中的一者的方法
US11690956B2 (en) * 2015-04-24 2023-07-04 Shl Medical Ag Sub-assembly of a medicament delivery device and a medicament delivery device
TW201700117A (zh) 2015-06-03 2017-01-01 賽諾菲阿凡提斯德意志有限公司 用於自動注射器的注射筒托架和組裝方法
HK1247139A1 (zh) * 2015-06-26 2018-09-21 Quio Technologies Llc 一种用於与多种不同的预填充支架在尺寸与操作上相兼容且具有可互换模件的自动注射器装置
EP3344312A1 (fr) * 2015-08-31 2018-07-11 Novo Nordisk A/S Dispositif de distribution de médicament avec précision de dose améliorée
US20180099094A1 (en) * 2016-10-12 2018-04-12 Abbvie Inc. Automatic injection device

Also Published As

Publication number Publication date
AU2019359801A1 (en) 2021-03-18
AU2019359801B2 (en) 2025-01-02
CA3109988A1 (fr) 2020-04-23
TWI846741B (zh) 2024-07-01
EP3866889A1 (fr) 2021-08-25
AU2025201784A1 (en) 2025-04-03
JP2022504805A (ja) 2022-01-13
US20210346596A1 (en) 2021-11-11
EA202191038A1 (ru) 2021-07-06
IL281895A (en) 2021-05-31
JP2024150483A (ja) 2024-10-23
AR130840A2 (es) 2025-01-22
CN112689523A (zh) 2021-04-20
SG11202101824VA (en) 2021-03-30
TW202031306A (zh) 2020-09-01
AR116703A1 (es) 2021-06-02
MX2021002791A (es) 2021-05-12
WO2020081480A1 (fr) 2020-04-23

Similar Documents

Publication Publication Date Title
EP3826589A4 (fr) Dispositif ophtalmique pour l'administration de médicaments
EP3437676A4 (fr) Dispositif d'administration de médicament liquide
EP3528732A4 (fr) Procédé et dispositif pour l'administration améliorée d'une composition
MA49949A (fr) Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament
MA50904A (fr) Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament
EP3793680C0 (fr) Dispositif d'administration de radio-embolisation
EP3520843A4 (fr) Dispositif d'administration de médicament liquide
MA50611A (fr) Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
MA50614A (fr) Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
MA51617A (fr) Mécanisme d'administration de médicament
MA47679A (fr) Détection de dose et identification de médicament pour dispositif d'administration de médicament
EP3354302A4 (fr) Dispositif d'administration de médicament liquide
EP3621656A4 (fr) Formulation pour l'administration d'un médicament pour les yeux
EP3354306A4 (fr) Dispositif d'administration de médicament et unité d'administration de médicament
EP3442481A4 (fr) Systèmes et procédés d'administration de médicaments à un oeil
EP3881883A4 (fr) Dispositif d'administration de solution medicamenteuse
EP3646907A4 (fr) Dispositif d'administration de médicament liquide et procédé permettant de fabriquer un dispositif d'administration de médicament liquide
EP3903856A4 (fr) Dispositif d'administration de médicament et système d'administration de médicament
EP3925643A4 (fr) Appareil d'administration de médicament liquide
EP3524295A4 (fr) Dispositif d'administration de médicament liquide et procédé de commande pour dispositif d'administration de médicament liquide
EP3906017A4 (fr) Dispositif d'administration de médicament par voie nasale
MA53227A (fr) Mécanisme d'activation pour dispositif d'administration de médicament
EP3471829A4 (fr) Système d'administration de médicaments pour l'administration d'agents antiviraux
MA55518A (fr) Dispositif d'administration de médicament avec système de dosage à engrenages
EP3661576A4 (fr) Nébuliseur médical pour administration rapide de médicament